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Interleukin (IL)-33 is the latest member of IL-1 cytokine family. In this study, the cloning, expression, puriﬁcation, and polyclonal
antibody preparation of mouse IL-33 were described. The coding region of IL-33 mature protein was cloned into the prokaryotic
expression vector pET-44. The recombinant protein, IL-33 containing a hexahistidine tag in the C-terminal, was expressed
in Escherichia coli. The expressed soluble protein was puriﬁed by immobilized metal-ion aﬃnity chromatography using Ni
2+-
nitrilotriacetic acid agarose. The rabbits were immunized with the puriﬁed recombinant protein. The obtained antiserum was
precipitatedbysaturatedammoniumsulfateandthenpuriﬁedbyProteinAaﬃnitychromatography.Thesensitivityandspeciﬁcity
of the antibodies were evaluated by enzyme-linked immunosorbent assay and immunohistochemistry. The high titer (1 : 32000)
polyclonalantibodieswithhighspeciﬁcitywereobtainedbyimmunizingrabbitswiththepuriﬁedrecombinantprotein.Signiﬁcant
expression of IL-33 was seen in mouse liver and lung tissues determined with the anti-IL-33. The production of the polyclonal
antibody against IL-33 provides a good tool for studying the biofunctions of IL-33.
Copyright © 2009 Xiaojin Liu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The classical interleukin (IL)-1 family cytokines, IL-1α and
IL-1β,a sw e l la sI L - 1 8 ,a r er e l a t e db ym e c h a n i s mo fo r i g i n ,
receptor structure, and signal transduction pathways utilized
[1]. IL-33 (also named IL-1F11), which belongs to IL-1 fam-
ily, is most closely related in structure to IL-18 and IL-1β [2].
IL-33 is also described as a nuclear factor expressed in high
endothelial venules (NF-HEV) [3] .T h eh u m a nI L - 3 3g e n ei s
located on chromosome 9p24.1, while its mouse counterpart
can be found on the syntenic chromosome 19qC1 region
[2]. The IL-33 cDNA sequences encode 270 and 266
amino acid polypeptides for human and mouse, respectively,
corresponding to full-length proteins with calculated masses
of 30 and 29.9kDa [2]. The proteins do not contain a signal
sequence for secretion, similar to the IL-1α,I L - 1 β, and IL-18
genes [4, 5]. The precursor protein (pre-IL-33) was cleaved
by caspase-1 into a mature 18-kDa protein (IL-33) in in vitro
experiments using a recombinant protein [2]. Human and
mouse IL-33 are 55% identical at the amino acid level. IL-
33 signals via the IL-1 receptor-related protein ST2 [2, 6]
and IL-1 receptor accessory protein [7]a c t i v a t eN F - κBa n d
mitogen-activated protein kinases to induce T helper type
2 (Th2)-associated cytokines [2, 8, 9]. Administration of
IL-33 to mice induces production of Th2 cytokines and
severepathologicalchangesinmucosalorgans[2].Moreover,
the ability of IL-33 to induce Th2 responses has functional
relevance in the context of intestinal helminth infection
[10]. IL-33 can promote survival, adhesion, and cytokine
production in human mast cells [11], but the mechanism
behind its involvement in inﬂammatory conditions remains
unclear. Otherwise, IL-33 can reduce the development of
atherosclerosis [12]. It is also a key mediator of immune
inﬂammatory hypernociception normally associated with a
Th1 type of response, revealing a hitherto unrecognized
function of IL-33 in a key immune pharmacological pathway
that may be amenable to therapeutic intervention [13].
In this study, the cloning and expression of mouse IL-33
gene in Escherichia coli (E. coli), puriﬁcation of recombinant
protein, and generation of polyclonal antibody against IL-
33 are described. The prepared antibody can be useful for
the study of expression and distribution of IL-33 in various
tissues at protein level and for the elucidation of its biofunc-
tions and regulation mechanism in inﬂammatory diseases.2 Journal of Biomedicine and Biotechnology
2.MaterialsandMethods
2.1. Materials. E. coli strain BL21 (DE3) and Ni-NTA His-
Bind Resins were obtained from Novagen (Madison, WI).
Trizol Reagent was purchased from Invitrogen (Carlsbad,
CA). Hotstar Taq DNA polymerase and QIAquick Gel
Extraction kit were purchased from Qiagen (Valencia, CA).
PrimeScript ﬁrst Strand cDNA Synthesis kit, restriction
endonucleases XhoI, NdeI, T4 DNA ligase, isopropyl-β-D-
thiogalactoside (IPTG), DNA Marker D2000, and Protein
Marker were from TaKaRa (Dalian, China). Lysozyme,
complete Freund’s adjuvant (CFA), and incomplete Freund’s
adjuvant (IFA) were obtained from Sigma (St. Louis, MO).
New Zealand rabbits were from South Medical University
(Guangzhou, China).
2.2. Plasmid Construction. Total cellular RNA was extract-
ed from spinal cord of BALB/c mouse according to
Trizol Reagent instructions. The coding region of
mouse IL-33 mature protein was ampliﬁed by reverse
transcription polymerase chain reaction (RT-PCR).
The ﬁrst strand of cDNA was synthesized using the
PrimeScript ﬁrst Strand cDNA Synthesis kit, and the
PCR reactions were carried out with a PTC-200 Peltier
Thermal Cycler (MJ Research, Waltham, MA). The
primer sequences of the IL-33 were designed with Primer
Premier 5.0 software. Primer 1 (5 -GGAATTCCATATG
ACATTGAGCATCCAAGGAAC-3 ) and primer 2 (5 -
CCGCTCGAGGATTTTCGAGAGCTTAAACA-3 )w e r es y n -
thesized by Invitrogen (Shanghai, China). Primer 1 was
synthesized with an NdeI site (shown in bold) and an
additional ATG for initiation of translation in italicized style.
Primer 2 was synthesized with an XhoI site (shown in bold).
The ampliﬁcation proﬁle included one initial hot-start
denaturation step at 94◦C for 15minutes, followed by 30
cycles of the following conditions: 94◦C for 30 seconds,
57◦C for 30 seconds, and 72◦C for 1minute, and a ﬁnal
extension at 72◦C for 10minutes. Plasmid pET-44 (Novagen,
Darmstadt, Germany) was digested with NdeIa n dXhoI
restriction enzymes. The large fragment was cut and puriﬁed
from agarose gel using the QIAquick Gel Extraction kit.
A recombinant plasmid was constructed by inserting the
ampliﬁed fragments (also digested with NdeIa n dXhoI)
into the NdeIa n dXhoI sites of pET-44 and transformed
into E. coli strain BL21 (DE3). The transformants (pET-44-
mIL-33) were conﬁrmed by colony PCR, restriction enzyme
digestion, and DNA sequencing. Expression in bacteria
results in the producing of recombinant IL-33 protein
containing a hexahistidine tag in the C-terminus.
2.3. Expression and Puriﬁcation of IL-33. A single colony of
successfully transformed E. coli was picked up and cultured
overnight at 37◦Ci nL u r i aB e r t a n i( L B )m e d i u m ,s u p p l e -
mented with 100μg/mL ampicillin. The culture mixture
was then inoculated to fresh LB medium (1 : 100 dilution)
containing ampicillin and grown at 37◦C under continuous
shaking, until the absorbance at 600nm reached 0.6–0.8.
To optimize the expression conditions, IL-33 expression was
induced by adding 1mM IPTG to the transformed E. coli
and the bacteria were incubated at 25◦Cf o rap e r i o do f
1, 2, 3, 4, 5, 6, 7, 8, and 9hours, respectively. The degree
of expression was evaluated by sodium dodecyl sulfate-
polyacrylamidegelelectrophoresis(SDS-PAGE).Tocompare
the protein dissolubility, the bacteria with pET-44-mIL-33
were also incubated at 37◦Co r2 5 ◦C.
After 7hours of induction at 25◦C, the cells were
harvested by centrifugation at 8,000×gf o r2 0 m i n u t e sa t
4◦C. The supernatant was discarded and the pellet was resus-
pended in lysis buﬀer consisting of 300mM NaCl, 50mM
NaH2PO4, 10mM imidazole, pH 8.0, and lysed by using
lysozyme,andincubatedfor30minutesatroomtemperature
(RT) with gentle shaking to assure thorough cell lysis. The
cell lysate was further disrupted by sonication on ice with
six 10-second pulses at high intensity with a 10seconds
cooling period between each burst. The suspension was
centrifuged at 12,000×g for 30minutes to remove insoluble
debris.
The supernatant was added to an Ni-NTA spin column
pre-equilibrated with the lysis buﬀer, and then they were
gently shaked on ice for 60minutes. The ﬂow-through was
collected for SDS-PAGE analysis. The column was then
washed with native wash buﬀer (300mM NaCl, 50mM
NaH2PO4, 20mM imidazole, pH 8.0). Finally, the bound
protein was eluted with native elution buﬀer (300mM
NaCl, 50 mM NaH2PO4, 250mM imidazole, pH 8.0) and
analyzed with 12% SDS-PAGE. Fractions were desalted and
concentrated by an ultraﬁltration device (Millipore Corpo-
ration, Bedford, MA). The concentration of IL-33 protein
was determined by Lowry method. N-terminal sequenc-
ing was performed by automated Edman degradation
method.
2.4. Production and Puriﬁcation of Polyclonal Antibodies
Against IL-33. The New Zealand white rabbits were given
intradermal injections of IL-33 protein (500μg/rabbit)
mixed with CFA in 1 : 1 ratio. After 2 week, the rabbits were
boosted subsequently 4 times with protein (200μg/rabbit)
mixed with IFA in 1 : 1 ratio at 2-weeks interval. Before
every immunization, blood samples were taken from the
marginalveinoftherabbitear,centrifuged,andtheserawere
obtained to determine the antibody titer by enzyme-linked
immunosorbent assay (ELISA). One week after the last
injection, antisera of the rabbits were collected and puriﬁed
by saturated ammonium sulfate (SAS) and then Protein A
Sepharose aﬃnity chromatography (Amersham Biosciences,
Piscataway, NJ) following manufacturer’s instructions.
2.5. Antiserum Titer Determination by ELISA. The titer of
antiserum was determined by an indirect ELISA. For each
well of the 96-well ELISA plate, 200ng of IL-33 protein
was diluted in 100μL of sodium bicarbonate solution
and incubated overnight at 4◦C. After three washes with
phosphate-buﬀered saline-(PBS-) Tween buﬀer (0.05%
Tween 20 in PBS), the wells were blocked using 100μLo f3 %
bovineserumalbuminfor1hourat37◦Candthenincubated
with 100μL polyclonal antibodies against IL-33 with diﬀer-
ent dilution (from 1 : 100 to 1 : 64,000) for 1.5 hours. TheJournal of Biomedicine and Biotechnology 3
wellswereincubatedwith50μL/wellhorseradishperoxidase-
(HRP-) conjugated goat antirabbit immunoglobulin (IgG,
1 : 250 dilution) for 1 hour at 37◦C after thoroughly washed.
After ﬁnal washes, 100μL/well tetramethyl benzidine (TMB)
solution was added for color development. After 10minutes,
the reaction was stopped by 100μL/well 2MH2SO4 and
the absorbance was measured at 450nm using a plate
reader (Molecular Devices). Ratio of antiserum versus
control serum absorbency greater than 2.1 was recognized as
positive.
2.6. Immunohistochemistry. In order to conﬁrm that the
polyclonal antibodies are able to recognize IL-33 protein
from tissues, immunohistochemistry was performed in nor-
mal BALB/c mice lung and liver tissues. We also examined
the IL-33 protein expression of plasmid pcDNA3.1-mIL-33
after delivery through hydrodynamics-based gene injection
in BALB/c mice [14, 15]. The plasmid pcDNA3.1-mIL-33
wasconstructedasforenamed,butwholemouseIL-33cDNA
was ampliﬁed by PCR and then inserted into mammalian
expression plasmid pcDNA3.1(+) (Invitrogen). Twenty-four
hours after plasmid injection, mice were anesthetized and
sacriﬁced. Liver and lung were harvested and ﬁxed in 10%
buﬀered formalin. After paraﬃn embedding, 5μms e c t i o n s
were cut. Immunohistochemistry on sections was performed
as described previously with some modiﬁcation [16]. Brieﬂy,
slides were dried in an oven (60◦C) before removing paraﬃn
in several changes of xylene. Slides were hydrated through
a series of graded alcohols to water, followed by incubation
with 0.5% hydrogen peroxide for 5minutes. Sections were
incubated with 5% bovine serum albumin (BSA) in PBS for
10minutes at RT to block nonspeciﬁc binding. After rinsing
with PBS, slides were incubated overnight at 4◦Cw i t hr a b b i t
anti-IL-33 polyclonal antibody (1 : 1,000 dilution in PBS
containing 5% BSA). After rinsing with PBST (PBS contain-
ing 0.01% Triton X-100), tissue sections were incubated for
40minutes at RT with HRP-conjugated goat antirabbit IgG
(1 : 100) and rinsed with PBST. Subsequently, slides were
stained with diaminobenzidine (DAB) and counterstained
withhematoxylin,dehydrated,andmounted.Brownstaining
was considered positive. For negative control, normal rabbit
serum or buﬀer alone were used in place of the primary
antibodies.
3. Results andDiscussion
3.1. Construction of Expression Plasmid pET-44-mIL-33. In
order to express recombinant IL-33 in E. coli, the mature
protein coding region of IL-33 was generated by PCR
and was cloned between NdeIa n dXhoI sites of pET-44
vector containing the coding sequence for a hexahistidine-
coding sequence in the C-terminal part. Ampliﬁcation
of the IL-33 gene by PCR produced a single ampliﬁed
480bp DNA fragment, coding for a mature IL-33 protein
of 160 amino acids. DNA sequencing revealed that the
cDNA was the reported sequences. The ﬁnal pET-44-mIL-
33 construct is able to express the recombinant IL-33 protein
in fusion with a hexahistidine tag and allow for metal aﬃnity
puriﬁcation.
KDa
97.2
66.4
44.3
29
20.1
14.3
M 123 456 7 89
Figure 1: SDS-PAGE analysis of recombinant IL-33 protein
expressed by E. coli. The expression was induced by 1mM IPTG
at 25◦Cf o rd i ﬀerent periods. Lane M: protein molecular weight
marker; lanes 1–9: whole cell lysates after 1, 2, 3, 4, 5, 6, 7, 8, and
9hours IPTG induction at 25◦C, respectively.
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Figure 2: SDS-PAGE analysis of IL-33 puriﬁcation and identiﬁca-
tion. Lane M, protein molecular weight marker; Lane 1: puriﬁed
IL-33; Lane 2: total cell lysate before induction at 25◦C; Lane 3:
supernatant fractions of total cell lysate after induction; Lane 4:
pellet fractions of total cell lysate after induction; Lane 5: total cell
lysate after induction at 25◦C.
3.2. Expression of the Protein. After induction with IPTG, E.
coli BL21 (DE3) transformed with pET-44-mIL-33 produced
a protein of approximately 18kDa as shown in Figure 1.
The size of the protein matched well with its theoretical
molecular weight. To determine the optimal induction
period, the bacteria were incubated with IPTG at 25◦Cf o r1 ,
2,3,4,5,6,7,8,and 9hours,respectively.Theresultsshowed
that while the incubation period was below 7hours, the
yield of the ∼18kDa protein was increased as the induction
time prolonged; but when the incubation time exceeded
7hours, the yield of the product was not signiﬁcantly raised
(Figure 1).
3.3. Puriﬁcation and Analysis of IL-33. The ﬁnal concentra-
tion of IPTG used in this experiment was 1mmol/L, and the4 Journal of Biomedicine and Biotechnology
KDa
97.2
66.4
44.3
29
20.1
M12 3
Figure 3: SDS-PAGE analysis of the polyclonal antibody. M:
molecular weight marker; 1: serum without puriﬁcation; 2: serum
puriﬁed with SAS; 3: polyclonal antibody after puriﬁcation by
aﬃnity chromatography.
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Figure 4: The titer of antiserum by ELISA. The antibody titer is
deﬁned as the highest dilution of serum at which the A450 ratio
(A450 of postimmunization sera/A450 of preimmunization sera) is
greater than 2.1.
bacteria were cultivated at 25◦C for 7 hours. Induced BL21
(DE3) cells at 25◦C can express the IL-33 protein (Figure 2,
lane 5). In contrast, noninduced BL21 (DE3) cells did not
express this fusion protein (Figure 2,l a n e2 ) .T h es o l u b l eI L -
3 3w a se x p r e s s e da th i g hl e v e l sa t2 5 ◦C( Figure 2,l a n e3 ) ,
but at low levels at 37◦C (data not shown). This was most
likely due to growth at 37◦C, which causes some protein to
accumulate as inclusion bodies, whereas incubation at 25◦C
decreases the rate of protein synthesis and leads to soluble
protein.
Ni-NTA aﬃnity chromatography was applied for puriﬁ-
cation of the IL-33 fusion protein. The target IL-33 protein
appeared as a single band on SDS-PAGE (Figure 2,l a n e1 ) ,
which is in agreement with the molecular weight reported
[2]. Polyhistidine tags form high-aﬃnity complexes with
immobilized divalent metalions (suchasNi2+ or Co2+), even
in the presence of high concentrations of chaotropic agents
(e.g., urea or guanidine hydrochloride), thereby allowing
isolation of tagged protein from a crude cellular extract
[17]. His-tagged IL-33 exists in the bacterial cells in two
forms: either soluble protein or inclusion bodies. The soluble
protein was incubated with the Ni-NTA agarose slurry
to allow binding of His-tagged IL-33. The purity of the
protein as determined by densitometry was greater than
95%. The yield of recombinant IL-33 was about 95mg
from 1L of bacterial culture. N-terminal sequencing of
the puriﬁed IL-33 revealed that the ﬁrst 20 residues were
identical to the mouse IL-33 sequence deduced from the
DNA (TLSIQGTSLLTQSPASLSTY).
3.4. Titer Analysis by ELISA. After immunizing rabbits with
recombinant IL-33 according to standard protocol, anti-IL-
33 serum was puriﬁed by SAS precipitation and Protein A
aﬃnity chromatography. The puriﬁed antibody had high
purity. The IgG fractions showed two bands, a heavy chain
(50 kDa) and a light chain (25kDa) on SDS-PAGE gel after
passing through the Protein A-Sepharose column (Figure 3).
Thetiteroftheobtainedanti-IL-33serumwasdeterminedby
ELISA. The antibody at diﬀerent dilutions (100- to 64,000-
fold) was reacted with an equal amount of the IL-33 protein
(0.2μg). The antibody titer is deﬁned as the highest dilution
ofserumatwhichtheA450ratio(A450ofpostimmunization
sera/A450 of preimmunization sera) is greater than 2.1. The
antibody titer was found to be approximately 1 : 32,000
(Figure 4).
3.5. Tissue Immunohistochemistry. IL-33 is a “dual-function”
cytokine that may function as both an intracellular
heterochromatin-associated nuclear factor and a potent
proinﬂammatory cytokine [3]. After immunohistochem-
istry was performed using the anti-IL-33 polyclonal anti-
body in mouse lung and liver tissues, there were brown
staining in nuclei or cytoplasm (Figures 5(b), 5(d), 5(f),
5(h)). Furthermore, there was a signiﬁcant increase of IL-
33 expression in hydrodynamics-injected mice with IL-
33 cDNA plasmid compared with normal mice (Figure 5).
Bronchial epithelial cells in lung and liver cells revealed
the strongest staining with anti-IL-33 antibody in hydro-
dynamics injected mice (Figures 5(h), 5(f)). No staining
was detected in tissues where no antibody or control
IgG was used in the primary layer (IgG control, Figures
5(a), 5(c), 5(e), 5(g)). Our results demonstrated that
the endogenous IL-33 protein in tissues could be specif-
ically recognized by our prepared anti-IL-33 polyclonal
antibodies.Journal of Biomedicine and Biotechnology 5
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 5: IL-33 immunostaining in mouse liver (a), (b), (e), (f) and lung (c), (d), (g), (h) tissues using the rabbit anti-IL-33 antibodies
(1:1,000) under a microscope (×400). Immunohistochemical analysis was performed in formalin-ﬁxed, paraﬃn-embedded livers and lungs
from normal mice and hydrodynamics-based gene injected mice after 24hours (n = 4). Staining of IL-33 in livers and lungs from normal
mice (b), (d) and hydrodynamics-injected mice (f), (h). Antibodies showed nuclear or cytoplasmic staining. Furthermore, there was a
signiﬁcant increase of IL-33 expression in hydrodynamics-injected mice (f), (h) compared with normal mice (b), (d). Control IgG showed
no stain (a), (c), (e), (g).
4. Conclusions
We have developed a procedure for the eﬃcient expression
and puriﬁcation of IL-33 using pET-44 vector and Ni-
NTA aﬃnity chromatography. Furthermore, we report the
production of speciﬁc anti-IL-33 antibody and the local-
ization of endogenous IL-33. It has been observed that IL-
33 mRNA is broadly expressed in many tissues but is more
restricted at the level of cell type, which includes pulmonary
smooth muscle cells, epithelial cells, dermal ﬁbroblasts,
keratinocytes,dendriticcells,andactivatedmacrophages[2].
IL-33 is also expressed in endothelial cells from chronically
inﬂamed rheumatoid arthritis synovium and Crohn’s disease
intestine [3, 18] and atherosclerotic tissues [12]. However,
very little information is available on the expression of IL-
33 protein in liver and lung tissues. To our knowledge
this is the ﬁrst report so far of production of polyclonal
antibody against full-length mouse IL-33 and IL-33 protein
expression in mouse liver and lung determined with anti-IL-
33 polyclonal antibodies. As IL-33 induces gene expression
of Th2-associated cytokines and pathological changes in
the lung [2], blockade of IL-33 may be a new therapeutic
strategy for bronchial asthma. We are investigating the
eﬀect of exogenously administered anti-IL-33 antibody in
a murine model of allergen-induced asthma [19]a n d
collagen-induced arthritis. This research may contribute to
elucidation of the biological mechanisms of IL-33 in human
inﬂammatory diseases in the future.
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